ATNM

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Actinium Pharmaceuticals Inc

NYSE MKT | ATNM

1.26

USD

$0.00

(

0.00%

)

At Close (As of Nov 7, 2025)

$41.18M

Market Cap

-

P/E Ratio

-1.31

EPS

$2.41

52 Week High

$1.02

52 Week Low

HEALTHCARE

Sector

ATNM Chart

Recent Chart
Price Action

ATNM Technicals

Tags:

ATNM Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$811K
Total Revenue $0
Cost Of Revenue $811K
Costof Goods And Services Sold $811K
Operating Income -$42M
Selling General And Administrative $12M
Research And Development $30M
Operating Expenses $41M
Investment Income Net -
Net Interest Income $3.9M
Interest Income $3.9M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $811K
Income Before Tax -$38M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$38M
Comprehensive Income Net Of Tax -
Ebit -$38M
Ebitda -$37M
Net Income -$38M

Revenue & Profitability

Earnings Performance

ATNM Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $77M
Total Current Assets $75M
Cash And Cash Equivalents At Carrying Value $73M
Cash And Short Term Investments $73M
Inventory -
Current Net Receivables -
Total Non Current Assets $2.4M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.6M
Other Non Current Assets -
Total Liabilities $44M
Total Current Liabilities $8.1M
Current Accounts Payable $7.6M
Deferred Revenue -
Current Debt -
Short Term Debt $1.2M
Total Non Current Liabilities $36M
Capital Lease Obligations $1.6M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.6M
Other Current Liabilities -$580K
Other Non Current Liabilities -
Total Shareholder Equity $33M
Treasury Stock -
Retained Earnings -$376M
Common Stock $31K
Common Stock Shares Outstanding $30M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$33M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $811K
Capital Expenditures $11K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$11K
Cashflow From Financing $29M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$38M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$811K
Total Revenue $0
Cost Of Revenue $811K
Costof Goods And Services Sold $811K
Operating Income -$42M
Selling General And Administrative $12M
Research And Development $30M
Operating Expenses $41M
Investment Income Net -
Net Interest Income $3.9M
Interest Income $3.9M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $811K
Income Before Tax -$38M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$38M
Comprehensive Income Net Of Tax -
Ebit -$38M
Ebitda -$37M
Net Income -$38M

ATNM Profile

Actinium Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Actinium Pharmaceuticals, Inc. is a leading clinical-stage biopharmaceutical firm focused on developing cutting-edge therapies for bone marrow transplantation and adoptive cell therapies, with a primary emphasis on hematologic malignancies. Based in New York, the company is advancing its proprietary antibody-radionuclide conjugate platform, aimed at improving patient outcomes in both transplantation and cancer care. With a promising pipeline of therapeutic candidates and strategic collaborations, Actinium is well-positioned to tackle significant unmet medical needs in the oncology sector, making it a compelling prospect for institutional investors seeking innovation in biopharmaceuticals.

BKYI
+51.56%
$0.96
RUBI
+39.37%
$0.31
AZI
-4.05%
$0.09
NVDA
+0.03%
$188.15
ASST
+4.13%
$1.51
ACHR
-7.88%
$8.18
BYND
+16.80%
$1.39
PFE
+0.97%
$24.85
ONDS
+10.66%
$5.81
TSLA
-3.67%
$429.52
VHAI
0.00%
$0.00
INTC
+2.38%
$38.13
PLUG
-4.92%
$2.50
RIVN
-1.29%
$15.22
GRAB
-1.24%
$5.56
F
+1.82%
$13.21
SOFI
+3.86%
$28.21
DNN
0.00%
$2.56
PLTR
+1.64%
$177.93
SNAP
+2.43%
$8.20
AAL
+3.80%
$13.65
BITF
-0.81%
$3.66
AXDX
-61.36%
$0.03
WTO
-7.52%
$0.04
NIO
-4.32%
$6.85
T
+0.34%
$24.82
BURU
-6.81%
$0.27
DVLT
+24.26%
$1.69
CHR
+0.15%
$0.06
ETHD
-9.69%
$4.38
RGTI
-1.71%
$33.77
BTG
+2.76%
$3.90
PBR
+5.88%
$12.85
JOBY
+3.98%
$14.89
PRMB
-18.64%
$14.40
AMD
-1.75%
$233.54
ADAP
-15.14%
$0.05
HOOD
-10.80%
$127.08
QBTS
+3.94%
$29.51
SOUN
-0.63%
$14.14
IONZ
-6.57%
$3.55
IREN
-6.94%
$62.31
NVTS
-11.26%
$7.84
AAPL
-0.48%
$268.47
KVUE
+2.61%
$16.89
RXRX
-1.32%
$4.55
MARA
-2.41%
$15.57
NEHC
+6.52%
$6.04
YDKG
-3.72%
$0.04
HIMS
-5.05%
$41.52
EPWK
+1.42%
$0.07
WULF
-2.38%
$13.94
MTVA
+6.30%
$0.90
BTBT
+3.63%
$3.14
DKNG
+8.64%
$30.40
EOSE
+19.42%
$18.26
XPEV
+9.63%
$23.89
BMNR
+7.69%
$40.24
BAC
-0.13%
$53.22
RMBL
+60.50%
$3.21
ABEV
+1.45%
$2.43
RIG
+1.92%
$3.97
CIFR
-5.34%
$20.54
ADD
-25.47%
$0.05
SMR
-8.04%
$29.85
NOK
-0.72%
$6.86
GOOGL
+0.15%
$284.75
TLRY
-5.46%
$1.21
SRM
+53.27%
$10.30
GPUS
+0.67%
$0.37
TTD
-6.31%
$43.00
QS
+4.49%
$16.61
ORGO
+44.73%
$5.63
SMCI
-1.42%
$39.76
CMG
+0.01%
$30.56
BBD
-0.56%
$3.51
PINS
+2.05%
$26.28
IONQ
+3.25%
$59.30
AMZN
+0.02%
$243.09
PLTZ
+13.94%
$7.11
FIG
-3.98%
$44.15
VALE
-0.69%
$12.14
WBD
+1.11%
$22.67
MU
-0.17%
$237.92
AMC
-7.50%
$2.40
PTON
+14.15%
$7.66
MTC
-6.85%
$2.58
RF
+2.18%
$24.84
IOVA
-0.43%
$2.29
META
+0.44%
$621.71
CGC
+7.33%
$1.17
WLGS
-5.57%
$0.04
HBAN
+1.75%
$15.69
CAN
+5.30%
$1.19
VZ
+0.55%
$40.04
QUBT
-2.20%
$12.86
NGD
+1.58%
$7.03
CLSK
+1.10%
$15.57
ETWO
0.00%
$3.30
AMCR
+1.76%
$8.36
BKYI
+51.56%
$0.96
RUBI
+39.37%
$0.31
AZI
-4.05%
$0.09
NVDA
+0.03%
$188.15
ASST
+4.13%
$1.51
ACHR
-7.88%
$8.18
BYND
+16.80%
$1.39
PFE
+0.97%
$24.85
ONDS
+10.66%
$5.81
TSLA
-3.67%
$429.52
VHAI
0.00%
$0.00
INTC
+2.38%
$38.13
PLUG
-4.92%
$2.50
RIVN
-1.29%
$15.22
GRAB
-1.24%
$5.56
F
+1.82%
$13.21
SOFI
+3.86%
$28.21
DNN
0.00%
$2.56
PLTR
+1.64%
$177.93
SNAP
+2.43%
$8.20
AAL
+3.80%
$13.65
BITF
-0.81%
$3.66
AXDX
-61.36%
$0.03
WTO
-7.52%
$0.04
NIO
-4.32%
$6.85
T
+0.34%
$24.82
BURU
-6.81%
$0.27
DVLT
+24.26%
$1.69
CHR
+0.15%
$0.06
ETHD
-9.69%
$4.38
RGTI
-1.71%
$33.77
BTG
+2.76%
$3.90
PBR
+5.88%
$12.85
JOBY
+3.98%
$14.89
PRMB
-18.64%
$14.40
AMD
-1.75%
$233.54
ADAP
-15.14%
$0.05
HOOD
-10.80%
$127.08
QBTS
+3.94%
$29.51
SOUN
-0.63%
$14.14
IONZ
-6.57%
$3.55
IREN
-6.94%
$62.31
NVTS
-11.26%
$7.84
AAPL
-0.48%
$268.47
KVUE
+2.61%
$16.89
RXRX
-1.32%
$4.55
MARA
-2.41%
$15.57
NEHC
+6.52%
$6.04
YDKG
-3.72%
$0.04
HIMS
-5.05%
$41.52
EPWK
+1.42%
$0.07
WULF
-2.38%
$13.94
MTVA
+6.30%
$0.90
BTBT
+3.63%
$3.14
DKNG
+8.64%
$30.40
EOSE
+19.42%
$18.26
XPEV
+9.63%
$23.89
BMNR
+7.69%
$40.24
BAC
-0.13%
$53.22
RMBL
+60.50%
$3.21
ABEV
+1.45%
$2.43
RIG
+1.92%
$3.97
CIFR
-5.34%
$20.54
ADD
-25.47%
$0.05
SMR
-8.04%
$29.85
NOK
-0.72%
$6.86
GOOGL
+0.15%
$284.75
TLRY
-5.46%
$1.21
SRM
+53.27%
$10.30
GPUS
+0.67%
$0.37
TTD
-6.31%
$43.00
QS
+4.49%
$16.61
ORGO
+44.73%
$5.63
SMCI
-1.42%
$39.76
CMG
+0.01%
$30.56
BBD
-0.56%
$3.51
PINS
+2.05%
$26.28
IONQ
+3.25%
$59.30
AMZN
+0.02%
$243.09
PLTZ
+13.94%
$7.11
FIG
-3.98%
$44.15
VALE
-0.69%
$12.14
WBD
+1.11%
$22.67
MU
-0.17%
$237.92
AMC
-7.50%
$2.40
PTON
+14.15%
$7.66
MTC
-6.85%
$2.58
RF
+2.18%
$24.84
IOVA
-0.43%
$2.29
META
+0.44%
$621.71
CGC
+7.33%
$1.17
WLGS
-5.57%
$0.04
HBAN
+1.75%
$15.69
CAN
+5.30%
$1.19
VZ
+0.55%
$40.04
QUBT
-2.20%
$12.86
NGD
+1.58%
$7.03
CLSK
+1.10%
$15.57
ETWO
0.00%
$3.30
AMCR
+1.76%
$8.36
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.